p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer

Francis R. Spitz, Geoffrey G. Giacco, Kenneth Hess, Lilly Larry, Tyvin A. Rich, Nora Janjan, Karen R. Cleary, John M. Skibber

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

This study was conducted to investigate the value of p53 immunohistochemical staining of pretreatment biopsy specimens in predicting the response of rectal cancer to chemoradiation. The study group comprised 42 patients with high-risk rectal cancer treated between July 1990 and July 1995 with a preoperative chemoradiation regimen of 45 Gy of external-beam irradiation and continuous-infusion 5-fluorouracil followed by surgical resection. p53 immunohistochemical staining was performed on pretreatment biopsy specimens. p53 immunohistochemical staining pattern and standard clinical and pathological parameters were correlated with extent of residual cancer in the surgical specimen. Twenty tumors were positive for p53 on immunohistochemical staining, 19 were negative, and 3 were locally positive. Thirteen patients experienced a complete response to chemoradiation. Aberrant p53 protein accumulation, as measured by immunohistochemical staining, correlated inversely with a complete pathological response to chemoradiation (P = 0.005; correlation coefficient = -0.43) and directly with an increased likelihood of residual cancer in the lymph nodes of surgical specimens (P = 0.02; correlation coefficient = 0.39). p53 immunohistochemical staining of pretreatment biopsy specimens correlates with the extent of residual disease after chemoradiation in patients with high-risk rectal cancer.

Original languageEnglish (US)
Pages (from-to)1685-1690
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number10
StatePublished - Oct 1997

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer'. Together they form a unique fingerprint.

Cite this